Can treatment with high doses of a cholesterol-lowering statin drug improve outcomes for patients with stroke caused by rupture and bleeding of brain aneurysms? An ongoing clinical trial will soon find out, according to an article in the May issue of Neurosurgery, official journal of the Congress of Neurological Surgeons.
[More]
Both fine-particle air pollution and noise pollution may increase a person's risk of developing cardiovascular disease, according to German researchers who have conducted a large population study, in which both factors were considered simultaneously.
[More]
The study comprised over 24,000 Finnish subjects and was led by Professor Samuli Ripatti. The results revealed that a panel of 28 genetic markers improved detection of individuals with high risk for coronary heart disease (10-year risk ≥20%) over traditional risk factors.
[More]
Statins, the most widely prescribed drugs worldwide, are often suggested to lower cholesterol and prevent heart disease in individuals with obesity, diabetes and metabolic syndrome, which is a combination of medical disorders including excess body fat and/or high levels of blood pressure, blood sugar and/or cholesterol.
[More]
The U.S. Food and Drug Administration and physicians continue to document that some patients experience fuzzy thinking and memory loss while taking statins, a class of global top-selling cholesterol-lowering drugs.
[More]
Men with prostate cancer who take cholesterol-lowering drugs called statins are significantly less likely to die from their cancer than men who don't take such medication, according to study led by researchers at Fred Hutchinson Cancer Research Center.
[More]
A laboratory study has shown for the first time that coenzyme Q10 offsets the cellular changes that are linked to a side-effect of some statin drugs - an increased risk of adult-onset diabetes.
[More]
An estimated 20 million Americans have chronic heartburn. About 2 million of these people have Barrett's esophagus, a precancerous condition that affects the tube that carries food from the mouth to the stomach.
[More]
High doses of a popular cholesterol-lowering drug significantly reduced the rate of acute kidney injury caused by dye used in imaging in acute coronary syndrome patients who underwent a coronary procedure, according to research presented today at the American College of Cardiology's 62nd Annual Scientific Session.
[More]
While two large clinical trials recently showed that adding niacin to statin therapy failed to improve clinical outcomes despite a significant increase in HDL-C levels, little is known about exactly why the increased HDL-C levels did not reduce the risk of cardiovascular events, including heart attack and stroke.
[More]
Heart patients who can't tolerate the side effects of cholesterol-lowering drugs may have a new option, according to a new study by researchers from the Intermountain Heart Institute at Intermountain Medical Center in Salt Lake City.
[More]
With March designated as Colorectal Cancer Awareness Month, the North Shore-LIJ Cancer Institute is enrolling people who were recently treated for colon cancer in a polyp prevention study. This National Cancer Institute (NCI)-sponsored study evaluates the cholesterol drug, rosuvastatin (Crestor), as a treatment to reduce the risk of colon cancer.
[More]
Drugs that combat ageing may be available within five years, following landmark work led by an Australian researcher.
[More]
Television advertising may drive over-diagnosis of high cholesterol and over-treatment with statins, according to a new study¹ by Dr. Jeff Niederdeppe from Cornell University in the US and colleagues. It appears that a trip to the doctor enquiring about statins advertised on TV often leads to a prescription.
[More]
Research published Online First in The Lancet provides new evidence that a substantial proportion of individuals with a clinical diagnosis of Familial Hypercholesterolaemia (FH) inherit a combination of small-effect changes in several genes (polygenic) rather than a large-effect mutation in a single gene (monogenic).
[More]
More people are meeting recommended goals in the three key markers of diabetes control, according to a study conducted and funded by the National Institutes of Health and the Centers for Disease Control and Prevention.
[More]
Researchers have found a genetic variant that doubles the likelihood that people will have calcium deposits on their aortic valve. Such calcification, if it becomes severe, can cause narrowing or a blockage of the aortic valve, a condition called aortic stenosis.
[More]
A single combination pill could reduce cardiovascular disease and stroke in Latin Americans by up to 21 percent at a cost of about $35 per quality adjusted life year gained, according to a study led by a University of Wisconsin School of Medicine and Public Health research team.
[More]
Esperion Therapeutics, the leading developer of small molecule therapies for the treatment of cardiometabolic disorders, today announced positive results of a recently completed Phase 2 clinical trial of ETC-1002 in patients with type 2 diabetes with LDL-C lowering of up to 43% compared to placebo.
[More]
Our review included analyses of drug and device studies conducted in humans. The drugs or devices could be compared to placebo or sham treatments, or other effective treatments. The drugs and devices examined for this review are used for a wide variety of clinical conditions, including cardiovascular and psychiatric diseases.
[More]